Urgently needed: a filter for the HIV-1 vaccine pipeline

被引：38

作者：

Moore, JP ^{[1
]}

Burton, DR

机构：

[1] Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA

[2] Scripps Res Inst, Dept Immunol, La Jolla, CA USA

[3] Scripps Res Inst, Dept Mol Biol, La Jolla, CA USA

来源：

NATURE MEDICINE | 2004年 / 10卷 / 08期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1038/nm0804-769

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Research groups worldwide are trying to make immunogens intended to elicit neutralizing antibody responses as part of a prophylactic vaccine to counter the spread of HIV-1. The relative merits of different designs can only be gauged properly through comparative studies, and particularly by evaluating human or animal antisera under identical, or comparable, conditions. Hence there is a need for assay standardization and for the creation of a centralized testing facility that could distribute consensus protocols and reagents.

引用

页码：769 / 771

页数：3

共 18 条

[1] HIV vaccine design and the neutralizing antibody problem [J].

Burton, DR ;

Desrosiers, RC ;

Doms, RW ;

Koff, WC ;

Kwong, PD ;

Moore, JP ;

Nabel, GJ ;

Sodroski, J ;

Wilson, IA ;

Wyatt, RT .

NATURE IMMUNOLOGY, 2004, 5 (03) :233-236

[2] Analysis of the antigen combining site: Correlations between length and sequence composition of the hypervariable loops and the nature of the antigen [J].

Collis, AVJ ;

Brouwer, AP ;

Martin, ACR .

JOURNAL OF MOLECULAR BIOLOGY, 2003, 325 (02) :337-354

[3] Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission [J].

Derdeyn, CA ;

Decker, JM ;

Bibollet-Ruche, F ;

Mokili, JL ;

Muldoon, M ;

Denham, SA ;

Heil, ML ;

Kasolo, F ;

Musonda, R ;

Hahn, BH ;

Shaw, GM ;

Korber, BT ;

Allen, S ;

Hunter, E .

SCIENCE, 2004, 303 (5666) :2019-2022

[4] Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy [J].

Dreyer, K ;

Kallas, EG ;

Planelles, V ;

Montefiori, D ;

McDermott, MP ;

Hasan, MS ;

Evans, TG .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 1999, 15 (17) :1563-1571

[5] Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials [J].

DSouza, MP ;

Livnat, D ;

Bradac, JA ;

Bridges, SH ;

Bryson, Y ;

Hanson, C ;

Matthews, T ;

Moore, J ;

Trkola, A ;

ZollaPazner, S ;

Gorny, M ;

Burton, D ;

Merigan, T ;

McNamara, J ;

Norcross, M ;

Posner, M ;

Robinson, J ;

ViraniKetter, N ;

Barbas, CF ;

Parren, P ;

Katinger, H .

JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (05) :1056-1062

[6] Occupancy and mechanism in anti body-mediated neutralization of animal viruses [J].

Klasse, PJ ;

Sattentau, QJ .

JOURNAL OF GENERAL VIROLOGY, 2002, 83 :2091-2108

[7] The need for a global HIV vaccine enterprise [J].

Klausner, RD ;

Fauci, AS ;

Corey, L ;

Nabel, GJ ;

Gayle, H ;

Berkley, S ;

Haynes, BF ;

Baltimore, D ;

Collins, C ;

Douglas, RG ;

Esparza, J ;

Francis, DP ;

Ganguly, NK ;

Gerberding, JL ;

Johnston, MI ;

Kazatchkine, MD ;

McMichael, AJ ;

Makgoba, MW ;

Pantaleo, G ;

Piot, P ;

Shao, YM ;

Tramont, E ;

Varmus, H ;

Wasserheit, JN .

SCIENCE, 2003, 300 (5628) :2036-2039

[8] Immunopathogenesis and immunotherapy in AIDS virus infections [J].

Letvin, NL ;

Walker, BD .

NATURE MEDICINE, 2003, 9 (07) :861-866

[9] Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells [J].

Mascola, JR ;

Louder, MK ;

Winter, C ;

Prabhakara, R ;

De Rosa, SC ;

Douek, DC ;

Hill, BJ ;

Gabuzda, D ;

Roederer, M .

JOURNAL OF VIROLOGY, 2002, 76 (10) :4810-4821

[10] Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1 [J].

Mascola, JR .

VACCINE, 2002, 20 (15) :1922-1925

← 1 2 →